IP Library Granted Patent US 7,588,776
Granted Patent B2
US 7,588,776 · App. 12/038,132 · Granted Sep 15, 2009

Pharmaceutical use of water-soluble fraction of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,588,776
App. No.
12/038,132
Granted
Sep 15, 2009
Kind
B2
Abstract

A pharmaceutical composition containing a water-soluble fraction of Graptopetalum and its use in treating a liver disease or condition, such as inflammation, steatosis, and fibrosis.

Claims (24)

1. A method of treating a subject suffering from or susceptible to a liver disease or medical condition, comprising administering an effective amount of a pharmaceutical composition comprising a water-soluble fraction of Graptopetalum to the subject, wherein the liver disease or medical condition is selected from the group consisting of liver inflammation, liver steatosis, liver fibrosis, liver cirrhosis, and hepatitis.

2. The method according to claim 1 , wherein the water-soluble fraction of Graptopetalum is an aqueous Graptopetalum extract.

3. The method according to claim 1 , wherein the Graptopetalum is Graptopetalum paraguayense.

4. The method according to claim 1 , wherein the liver disease or medical condition is liver inflammation.

5. The method according to claim 1 , wherein the liver disease or medical condition is liver steatosis.

6. The method according to claim 1 , wherein the liver disease or medical condition is liver fibrosis.

7. The method according to claim 1 , wherein the liver disease or medical condition is liver cirrhosis.

8. The method according to claim 1 , wherein the liver disease or medical condition is hepatitis.

9. The method according to claim 8 , wherein the hepatitis is hepatitis B.

10. The method according to claim 1 , wherein the pharmaceutical composition is administered orally.

11. The method according to claim 2 , wherein the aqueous Graptopetalum extract is prepared by:

(a) freeze drying a whole Graptopetalum plant to form a dried Graytopetalum plant;

(b) grinding the dried Graptopetalum plant to form a Graptopetalum powder;

(c) lyophilizing the Graptopetalum powder to produce a lyophilized powder;

(d) extracting the lyophilized powder with water to obtain a Graptopetalum extract; and

(e) lyophilizing the Graptopetalum extract.

12. The method according to claim 11 , wherein the Graptopetalum is Graptopetalum paraguayense.

13. The method according to claim 11 , wherein the liver disease or medical condition is liver inflammation.

14. The method according to claim 11 , wherein the liver disease or medical condition is liver steatosis.

15. The method according to claim 11 , wherein the liver disease or medical condition is liver fibrosis.

16. The method according to claim 11 , wherein the liver disease or medical condition is liver cirrhosis.

17. The method according to claim 11 , wherein the liver disease or medical condition is hepatitis.

18. The method according to claim 17 , wherein the hepatitis is hepatitis B.

19. The method according to claim 11 , wherein the pharmaceutical composition is administered orally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2012
From: HSU, SHIH-LAN, DR.
To: TAICHUNG VETERANS GENERAL HOSPITAL; NUGENTEK LIFESCIENCE(TAIWAN) CO., LTD.
Reel/Frame 028057/0922 →
Continuity (2)
Continuation In Part 1093179100 · Aug 31, 2004
Related Publication 20080160112A1 · Jul 3, 2008